» Articles » PMID: 18775310

Chemical and Biological Approaches Synergize to Ameliorate Protein-folding Diseases

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 2008 Sep 9
PMID 18775310
Citations 206
Authors
Affiliations
Soon will be listed here.
Abstract

Loss-of-function diseases are often caused by a mutation in a protein traversing the secretory pathway that compromises the normal balance between protein folding, trafficking, and degradation. We demonstrate that the innate cellular protein homeostasis, or proteostasis, capacity can be enhanced to fold mutated enzymes that would otherwise misfold and be degraded, using small molecule proteostasis regulators. Two proteostasis regulators are reported that alter the composition of the proteostasis network in the endoplasmic reticulum through the unfolded protein response, increasing the mutant folded protein concentration that can engage the trafficking machinery, restoring function to two nonhomologous mutant enzymes associated with distinct lysosomal storage diseases. Coapplication of a pharmacologic chaperone and a proteostasis regulator exhibits synergy because of the former's ability to further increase the concentration of trafficking-competent mutant folded enzymes. It may be possible to ameliorate loss-of-function diseases by using proteostasis regulators alone or in combination with a pharmacologic chaperone.

Citing Articles

frameshift variants impair GABA receptor proteostasis.

Williams M, Wang Y, Kang J, Perryman J, Mu T bioRxiv. 2024; .

PMID: 39651292 PMC: 11623673. DOI: 10.1101/2024.11.28.625971.


High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease.

Williams D, Glasstetter L, Jong T, Chen T, Kapoor A, Zhu S Proc Natl Acad Sci U S A. 2024; 121(42):e2406009121.

PMID: 39388267 PMC: 11494340. DOI: 10.1073/pnas.2406009121.


Pharmacological chaperones restore proteostasis of epilepsy-associated GABA receptor variants.

Wang Y, Seibert H, Ahn L, Schaffer A, Mu T Pharmacol Res. 2024; 208:107356.

PMID: 39216838 PMC: 11457296. DOI: 10.1016/j.phrs.2024.107356.


A PIKfyve modulator combined with an integrated stress response inhibitor to treat lysosomal storage diseases.

Hou W, Massey L, Rhoades D, Wu Y, Ren W, Frank C Proc Natl Acad Sci U S A. 2024; 121(34):e2320257121.

PMID: 39150784 PMC: 11348278. DOI: 10.1073/pnas.2320257121.


The proteostasis interactomes of trafficking-deficient variants of the voltage-gated potassium channel K11.1 associated with long QT syndrome.

Egly C, Barny L, Do T, McDonald E, Knollmann B, Plate L J Biol Chem. 2024; 300(7):107465.

PMID: 38876300 PMC: 11284683. DOI: 10.1016/j.jbc.2024.107465.


References
1.
Brown C, Welch W . Correcting temperature-sensitive protein folding defects. J Clin Invest. 1997; 99(6):1432-44. PMC: 507959. DOI: 10.1172/JCI119302. View

2.
Bouvier M . When an inhibitor promotes activity. Chem Biol. 2007; 14(3):241-2. DOI: 10.1016/j.chembiol.2007.03.004. View

3.
Kaufman R . Orchestrating the unfolded protein response in health and disease. J Clin Invest. 2002; 110(10):1389-98. PMC: 151822. DOI: 10.1172/JCI16886. View

4.
Bush K, GOLDBERG A, Nigam S . Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem. 1997; 272(14):9086-92. DOI: 10.1074/jbc.272.14.9086. View

5.
Yan F, Lin C, Cartier E, Shyng S . Role of ubiquitin-proteasome degradation pathway in biogenesis efficiency of {beta}-cell ATP-sensitive potassium channels. Am J Physiol Cell Physiol. 2005; 289(5):C1351-9. PMC: 1350484. DOI: 10.1152/ajpcell.00240.2005. View